3 hours Capricor Therapeutics (NASDAQ:CAPR) Rating Reiterated by HC Wainwright MarketBeat
HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a research report on Wednesday.
HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Capricor Therapeutics in a research report on Wednesday.